New Shot-in-Tumor combo aims to beat melanoma before surgery
NCT ID NCT07230613
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests injecting two immunotherapy drugs (ipilimumab and nivolumab) directly into melanoma tumors before surgical removal. The goal is to shrink or eliminate the cancer while reducing the severe side effects that can occur when these drugs are given through a vein. About 50 adults with stage III melanoma that can be surgically removed will receive up to three injections over three weeks, then have surgery. Researchers will check if the tumor is gone or mostly gone after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab and nivolumab (immunotherapy drugs)
What this could lead to
If successful, this approach could offer a safer, more effective way to shrink melanoma tumors before surgery, potentially reducing recurrence and avoiding harsh side effects.
What could go wrong
This is a small, early-phase trial (50 participants) testing a new injection method. The treatment may not work as hoped, could cause unexpected side effects, or delay surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA, STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
RECRUITINGVillejuif, 94805, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••